GDRX - NASDAQ
GoodRx Holdings, Inc.
$2.81
-4.7%GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.
At a Glance
Live SnapshotGoodRx Holdings, Inc. Management Team
Mr. Romin Nabiey
Chief Accounting Officer
Compensation
$434,736
Mr. Christopher A. McGinnis
Chief Financial Officer & Treasurer
Mr. Ryan Sullivan
Chief Marketing Officer
Ms. Vina M. Leite
Chief People Officer
Mr. Nitin Shingate
Chief Technology Officer
Mr. Trevor Bezdek
Co-founder & Co-Chairman of the Board
Compensation
$853,918
Mr. Douglas Joseph Hirsch
Co-founder & Director
Compensation
$5,440
Ms. Aubrey Reynolds
Director of Investor Relations
Ms. Wendy Barnes
President, Chief Executive Officer & Director
Ms. Gracye Cheng
Senior Vice President, General Counsel & Secretary
GoodRx Holdings, Inc. Insider Positioning
During the last 12 months, insiders have sold $92K worth of GDRX shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
8.6K
34.28K
-34K
-$34K
9-12 Months
0
0.00
13.5K
57.60K
-58K
-$58K
Top Buyers
No buying activity
Top Sellers
Spectrum Equity Vii, L.P.
10 Percent Owner
$92K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $92K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
1 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
GDRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 29, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 23, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 25, 2024 | December 31, 2023 | 2023 | |
DEF 14A DEF 14A N/A | May 01, 2023 | May 01, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 27, 2022 | June 14, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 27, 2021 | June 10, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.